Study to Evaluate the Efficacy of an Avocado Dietary Supplement

NCT07354308 | Active Not Recruiting

• 1 other identifier: 20710
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This 16-week, randomized, triple-blinded, placebo-controlled study evaluates the effects of an avocado dietary supplement (Metavo) on healthy weight and blood glucose management in overweight adults. The study includes body measurements, questionnaires, blood tests, and CGM monitoring to assess metabolic outcomes and participant-reported perceptions of well-being.

Conditions

Overweight; Metabolic Health; Insulin Resistance

Keywords

Weight Management; Glucose Metabolism; avocado

Outcome Measures

Primary Outcomes (11)

• Change in Body Mass

  Measured via Withings Smart Scale. Participants will weigh themselves daily for 3 consecutive days each week. If the first two values are similar, their average is used. If they differ by ≥10 lbs, the third value is used to determine the average.

  Baseline through Week 16

• Change in Average Blood Glucose

  Change in average blood glucose levels measured using a Continuous Glucose Monitor (CGM). Average glucose will be calculated over each time period and the change from pre-baseline to Weeks 14-16 will be reported.

  2 weeks before Baseline and Weeks 14-16

• Change in Hemoglobin A1C (HbA1C)

  Assessed via blood samples at Labcorp or via home phlebotomy.

  Baseline and Week 16

• Change in Fasting Insulin

  Assessed via blood samples at Labcorp or via home phlebotomy.

  Baseline and Week 16

• Change in Lipid Panel

  Includes Cholesterol, LDL, VLDL, HDL, and triglycerides. Measured via Labcorp or home phlebotomy.

  Baseline and Week 16

• Change in hs-CRP

  High-sensitivity C-reactive protein measured via Labcorp or home phlebotomy.

  Baseline and Week 16

• Change in Fasting GLP-1 Levels

  Only measured in the home phlebotomy subgroup using InterScience Institute lab testing.

  Baseline and Week 16

• Change in Waist Circumference

  Measured with a tape measure.

  Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

• Change in Time in Range (TIR)

  Change in percentage of time that glucose levels are within the target range, measured using a CGM. TIR will be computed as the percentage of total CGM readings within the target range during the specified time periods.

  2 weeks before Baseline and Weeks 14-16

• Change in Time Below Range (TBR)

  Change in percentage of time that glucose levels are below the target range, measured using a CGM. TBR will be calculated as the percentage of total CGM readings below the target range.

  2 weeks before Baseline and Weeks 14-16

• Change in Time Above Range (TAR)

  Change in percentage of time that glucose levels are above the target range, measured using a CGM. TAR will be calculated as the percentage of total CGM readings above the target range.

  2 weeks before Baseline and Weeks 14-16

Secondary Outcomes (11)

• Change in Quality of Life

  Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

• Change in Physical Activity

  Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

• Change in Eating Habits

  Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

• Change in Food Cravings

  Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

• Change in Self-Reported Mood, Energy, and Health

  Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

Study Arms (2)

Metavo Supplement Group

EXPERIMENTAL

Participants in this group will receive the Metavo dietary supplement for 16 weeks.

Dietary Supplement: Metavo Supplement

Placebo Group

PLACEBO COMPARATOR

Participants in this group will receive placebo capsules that are visually matched to the Metavo supplement for 16 weeks.

Dietary Supplement: Placebo

Interventions

Metavo Supplement DIETARY_SUPPLEMENT

Participants will take 8 Intervention capsules per day (4 in the morning, 4 in the afternoon)

Metavo Supplement Group

Placebo DIETARY_SUPPLEMENT

Participants will take 8 placebo capsules per day (4 in the morning, 4 in the afternoon)

Placebo Group

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Be male or female
• Be aged between 18 and 70 years of age
• Be classified as overweight or obese with a BMI of ≥25.0 and ≤32 kg/m2.
• Have a stable weight defined as \<10% change in body weight in three months prior to the study start date.
• Willing to follow the provided diet and exercise guidelines.
• Willing to not consume avocados throughout the trial and for two weeks prior to Baseline
• Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
• Willing to stop any products, any prescription medication, or supplements that target weight management, blood sugar control, and/or aim to improve insulin during the test period.
• Willing to avoid introducing any new products or any new forms of prescription medication or supplements that target weight management, blood sugar control, and/or aim to improve insulin during the test period.
• Not currently partaking in another research study and will not be partaking in any other research study for the next 16 weeks and at any point during this study's duration.
• Must have someone available to take front and side profiles of the torso.
• Must have a smart phone or camera capable of taking photos of the torso.
• Resides in the United States.

You may not qualify if:

• Anyone with diagnosed Type I or Type II diabetes.
• Allergic to avocados
• Anyone with any allergies or sensitivities to any of the study product ingredients.
• Any women who are pregnant, breastfeeding, or trying to conceive
• Anyone unwilling to follow the study protocol.
• Has stopped using hormonal birth control in the past month.
• Anyone with a history of substance abuse.
• Anyone who is currently a smoker or has been a smoker in the past 6 months.
• Anyone with chronic health conditions that could impact participation in the study, such as oncological, psychiatric, metabolic, hypertension, or cardiovascular disorders, cancer, autoimmune disease, HIV, Hepatitis B, and/or C, kidney and/or liver, gastrointestinal, gastroesophageal reflux, blood/bleeding disorders, gout, or mental health disorders.
• Anyone who has had any major illness in the last 3 months.
• Anyone who drinks heavily (i.e., 8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
• Current use of prescribed medications as listed below: Weight loss prescription medication (within 3 months of baseline). Anticoagulants and coagulants (within 4 weeks of baseline).
• Anyone who has used any cannabis products (medical or recreational) in the past month.

Sponsors & Collaborators

• SP Nutraceuticals Inc.: lead
• Citruslabs: collaborator

Study Sites (1)

Citruslabs

Las Vegas, Nevada, 89118, United States

Location

MeSH Terms

Conditions

Overweight; Insulin Resistance

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 6, 2025
• First Posted: January 21, 2026
• Study Start: May 1, 2025
• Primary Completion: January 1, 2026
• Study Completion: January 1, 2026
• Last Updated: January 21, 2026

Record last verified: 2026-01

Locations

US (1)